EMB 06
Alternative Names: EMB-06Latest Information Update: 15 Jun 2025
At a glance
- Originator EpimAb Biotherapeutics
- Class Antineoplastics; Bispecific antibodies; Immunotherapies
- Mechanism of Action Antibody-dependent cell cytotoxicity
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Phase I/II Multiple myeloma
Most Recent Events
- 22 May 2025 Epimab Biotherapeutics terminates a phase I/II trial in Multiple myeloma (Second-line therapy or greater) in China and Australia (IV) due to company's resource optimization and product's development change (NCT04735575)
- 07 Dec 2024 Efficacy, adverse event, pharmacokinetics and pharmacodynamics data from phase I/II trial in Multiple myeloma presented at the 66th American Society of Hematology Annual Meeting and Exposition (ASH-Hem-2024)
- 07 Sep 2022 Phase-I/II clinical trials in Multiple myeloma (Second-line therapy or greater) in China (IV) (NCT04735575; EpimAb pipeline, before September 2022)